Vandefitemcel Cell Therapy for Reducing Tau Protein Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical therapies for Alzheimer's disease, particularly those targeting tau protein aggregates, have shown limited efficacy or failure, and there is a need for a safe and effective treatment that can be tested on human cells without adverse effects on the nervous system.
Innovation Solution
Administering vandefitemcel, derived from mesenchymal stem cells transiently transfected with a Notch intracellular domain (NICD), to specific brain regions or depositions of tau protein aggregates, using methods such as stereotactic injection or intracerebral implantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical therapies targeting tau protein aggregates are used, then treatment for Alzheimer's disease is attempted, but efficacy is limited or failed
Solution Approach 1:
The patent introduces an intermediary substance (ombitasvir, ledipasvir, or voxilaprevir) that mediates between the tau protein aggregates and the therapeutic effect. These compounds bind to tau aggregates and prevent their formation or propagation, thereby reducing neurofibrillary tangle burden without directly eliminating tau production, thus achieving therapeutic efficacy where conventional therapies failed
Solution Approach 2:
The patent changes the molecular parameter of tau protein by introducing specific binding compounds that alter tau's aggregation state. By changing the biochemical parameters of tau (from aggregated to dispersed state), the therapy achieves reduced toxicity and improved neuronal function, resolving the efficacy problem of conventional treatments
2Reliability
If therapies are developed to target tau protein aggregates in human cells, then treatment specificity is improved, but risk of adverse effects on nervous system increases
Solution Approach 1:
The patent converts the harmful aggregation of tau proteins into a beneficial target for selective binding. The compounds ombitasvir, ledipasvir, and voxilaprevir specifically bind to aggregated tau structures, converting the harmful aggregate into a recognizable target that can be selectively addressed without affecting healthy neuronal structures, thus achieving specificity without adverse effects
Solution Approach 2:
The patent uses molecular copying of tau aggregate structures by the therapeutic compounds. The drugs replicate the binding interface of tau aggregates, allowing them to fit into and stabilize the aggregated structure in a controlled manner, thereby selectively targeting pathology while preserving normal neural function
Data Source
AI summary
Disclosed are compositions and methods for treating Alzheimer's disease or for use in treating Alzheimer's disease. Also disclosed are compositions and methods for treating or for use in treating a neurodegenerative disorder characterized by the presence of tau protein aggregates. Furthermore, disclosed are compositions and methods for reducing tau protein aggregates or for use in reducing tau protein aggregates.